Dimerix Bioscience Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Dimerix Bioscience Ltd updates on initial public offer
Dimerix Bioscience Ltd:Says it is undertaking an initial public offer.Dimerix lodged a prospectus dated 12 June 2014 with the Australian Securities and Investments Commission (ASIC) in relation to the offer (Prospectus).Offer will only be made pursuant to the prospectus and full details of the offer are set out in prospectus.Closing date for offer and closing date for ASX bookbuild period has been extended to Aug. 1 unless closed earlier at the discretion of directors.
Latest Developments for Dimerix Bioscience Ltd
Latest Key Developments in Biotechnology
- Minerva Neurosciences Inc announces completion of FDA review of investigational new drug application for MIN-202 and plans for first U.S.-based clinical trial
- Genetic Technologies Ltd announces divestment of Australian heritage business to Primary Health Care Ltd's subsidiary
- Starpharma Holdings Ltd completes A$18 mln placement; SPP to follow
- Dermira Inc sees IPO price between $14.00 and $16.00 per share - Form S-1/A
- Share this
- Digg this